4.4 Article

SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion

Journal

Publisher

SPRINGER
DOI: 10.1007/s00417-021-05494-5

Keywords

Central retinal vein occlusion; Hemiretinal vein occlusion; Macular thickness fluctuation; Visual acuity; Anti-VEGF treatment; Macular edema

Categories

Funding

  1. National Eye Institute (National Institutes of Health, Department of Health and Human Services) [U10EY023529, U10EY023533, U10EY023521]
  2. Research to Prevent Blindness, Inc.
  3. Regeneron, Inc
  4. Allergan, Inc

Ask authors/readers for more resources

Greater fluctuations in central subfield thickness as assessed by standard deviation and Zigzag measures were negatively associated with Month 12 visual acuity letter score. However, early post-treatment visual acuity letter score is a stronger predictor of visual acuity outcomes than the central subfield thickness fluctuation measures.
Purpose To evaluate macular thickness fluctuations and their association with visual acuity outcome in eyes with macular edema (ME) secondary to central (CRVO) or hemiretinal vein occlusion (HRVO) treated initially with intravitreal aflibercept or bevacizumab. Methods Post hoc analysis of 362 patients with ME secondary to CRVO or HRVO initially randomized to six monthly intravitreal injections of aflibercept or bevacizumab. Three spectral domain optical coherence tomography (SD-OCT) central subfield thickness (CST) fluctuation measures were investigated over Months 1-12: standard deviation (SD), number of turning points (T) for each participant, and a measure denoted as Zigzag reflecting the magnitude of alternating ups and downs in a participant's CST. Main outcome measure is Month 12 visual acuity letter score (VALS). Results More fluctuations occurred in eyes randomized to bevacizumab than aflibercept: SD (59.98 vs 32.12; p < 0.0001), T (4.03 vs 3.53; p = 0.02) and Zigzag (24.91 vs 11.60; p = 0.0003). Month 12 VALS is significantly lower for the 4th (highest) quartile of the CST fluctuation measure than for the 1st (lowest) quartile for both SD (mean difference in VALS of 7.87; 95% confidence interval: 3.03, 12.70) and Zigzag (mean difference in VALS of 5.11; 95% confidence interval: 0.29, 9.93). SD and Zigzag quartiles were no longer significantly different after Month 1 VALS was added to the regression analysis. Conclusions Greater CST fluctuation as assessed by SD and Zigzag was negatively associated with Month 12 VALS. However, early post-treatment VALS is a stronger predictor of VALS outcomes than the CST fluctuation measures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available